5-Fluorouracil degradation rate could predict toxicity in stages II–III colorectal cancer patients undergoing adjuvant FOLFOX-Reference-Cited by-同舟云学术

5-Fluorouracil degradation rate could predict toxicity in stages II–III colorectal cancer patients undergoing adjuvant FOLFOX

Published:2017-03 Issue:3 Volume:28 Page:322-326
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Onesti Concetta E.,Botticelli Andrea,La Torre Marco,Borro Marina,Gentile Giovanna,Romiti Adriana,Lionetto Luana,Petremolo Antonella,Occhipinti Mario,Roberto Michela,Falcone Rosa,Simmaco Maurizio,Marchetti Paolo,Mazzuca Federica

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference31 articles.

1. 5-Fluorouracil: mechanisms of action and clinical strategies;Longley;Nat Rev Cancer,2003

2. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency;Van Staveren;Pharmacogenomics J,2013

3. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group;Schwab;J Clin Oncol,2008

4. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity;Cho;Ther Drug Monit,2007

5. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD;Saif;Cancer Genomics Proteomics,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays;International Journal of Molecular Sciences;2022-11-11

2. Drug–Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN® System Comprehensive Approach;Pharmaceuticals;2021-01-15

3. Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?;Clinical Pharmacology & Therapeutics;2020-11-12

4. Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy;Frontiers in Oncology;2020-08-04

5. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine;Cancer Chemotherapy and Pharmacology;2020-06-11